MedPath

Blood Test to Measure DNA Damage in Blood

Terminated
Conditions
Prostate Cancer
Registration Number
NCT00523471
Lead Sponsor
AHS Cancer Control Alberta
Brief Summary

To check the radiosensitivity level in individual patients based on their DNA damage level.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
40
Inclusion Criteria
  • prostate cancer diagnosis
  • undergoing radiotherapy
  • agree to participate in study
Exclusion Criteria
  • not willing to participate
  • not undergoing radiotherapy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath